Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)

TRAILBLAZER-ALZ 5

This trial is Currently recruiting
Registration number NCT05508789

Program & service

This trial is being run with the Brain service, and as part of the Brain program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Associate Professor David Darby

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.